Companies
Outlook Therapeutics: FDA to Decide on Eye Drug Lytenava on July 29
Outlook Therapeutics faces a pivotal July: shareholders vote on capital increase on the 16th and FDA decides on Lytenava on the 29th.
Latest Biotechnology news
2 articles
CriteriaCaixa will invest 300 million in scientific and technological startups through Criteria Bio Ventures and Criteria Venture Tech, focusing on Spain.
Outlook Therapeutics faces a pivotal July: shareholders vote on capital increase on the 16th and FDA decides on Lytenava on the 29th.